Hilltop National Bank Sells 122 Shares of Novo Nordisk A/S (NYSE:NVO)

Hilltop National Bank trimmed its stake in Novo Nordisk A/S (NYSE:NVO) by 0.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,576 shares of the company’s stock after selling 122 shares during the quarter. Hilltop National Bank’s holdings in Novo Nordisk A/S were worth $1,770,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of NVO. Natixis Advisors LLC raised its stake in shares of Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after buying an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC increased its holdings in Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after acquiring an additional 19,870 shares during the last quarter. Versant Capital Management Inc bought a new stake in Novo Nordisk A/S in the 4th quarter valued at about $86,000. Zions Bancorporation N.A. lifted its holdings in Novo Nordisk A/S by 57.0% during the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after purchasing an additional 6,726 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its stake in shares of Novo Nordisk A/S by 14.8% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after purchasing an additional 37,346 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 1.1 %

NYSE NVO traded up $0.91 during trading hours on Friday, reaching $86.55. 2,646,449 shares of the company’s stock traded hands, compared to its average volume of 6,717,778. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a 50-day simple moving average of $100.86 and a 200 day simple moving average of $119.79. Novo Nordisk A/S has a 52-week low of $81.50 and a 52-week high of $148.15. The firm has a market cap of $388.40 billion, a PE ratio of 28.01, a PEG ratio of 1.37 and a beta of 0.45.

Analyst Upgrades and Downgrades

Several research analysts recently commented on NVO shares. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday. BMO Capital Markets cut their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.